AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15793606
Drug: HR 0‐(beta‐hydroxyethyl)‐rutosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR 0‐(beta‐hydroxyethyl)‐rutosides (1 g/day)
Trial: 15793606
Drug: HR 0‐(beta‐hydroxyethyl)‐rutosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR 0‐(beta‐hydroxyethyl)‐rutosides (2 g/day)
Trial: 10431768
Drug: Interferon-beta1a treatment
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta1a treatment
Trial: 7593528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg gemeprost by vaginal pessary (group I)
Trial: 2259825
Drug: Fenoterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (2.5 mg) with saline to complete 3 ml given through a jet nebulizer; followed by an additional dose (1 mg) through a 500 ml spacer 30 minutes later
Trial: 2259825
Drug: Fenoterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (2.5 mg) with saline to complete 3 ml given through a spacer first; followed by an additional dose (1 mg) through a jet nebulizer 30 minutes later
Trial: 6357964
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate tablets
Trial: 22674146
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) - epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) for 4 cycles (EC-T)
Trial: 22674146
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) - exemestane 25 mg daily for 24 weeks (combined with goserelin in premenopausal patients)
Trial: 11844818
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus weekly CDDP chemotherapy (40 mg/m(2))
Trial: 11844818
Drug: RT without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT without chemotherapy
Trial: 10076721
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by adjusted locoregional treatment
Trial: 10076721
Drug: Initial mastectomy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial mastectomy followed by adjuvant chemotherapy
Trial: 7672547
Drug: Nd: YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd: YAG laser therapy
Trial: 7672547
Drug: Injection-assisted piecemeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection-assisted piecemeal polypectomy
Trial: 27996339
Drug: Bowen systemic
RxNorm normalized name: potassium sulfate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bowen systemic family therapy (eight 90‐minute sessions)
Trial: 23200124
Drug: Preoperative carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrate treatment (PCT) ≥50 g oral carbohydrates 2-4 h pre-anaesthesia
Trial: 23200124
Drug: Preoperative carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrate treatment (PCT)
Trial: 19419595
Drug: Ziprasidone (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80-160 mg/d)
Trial: 18716688
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg tobramycin twice‐daily continuous treatment
Trial: 18716688
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment
Trial: 17152857
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 mg orally) given to female subjects 1 hour before post-TST
Trial: 8287567
Drug: Biosynthetic GH
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic GH replacement therapy (0.25 IU/kg/week)
Trial: 2882294
Drug: 1 microgram,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma), given by intravenous infusion twice a week for four weeks
Trial: 2882294
Drug: 1 microgram,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma)
Trial: 31385885
Drug: Pinaverium Bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium Bromide 100 mg plus Simethicone 300 mg (PB+S)
Trial: 30141237
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (2 mg/day) of aripiprazole adjunctive to antidepressant therapy
Trial: 26316698
Drug: Biphasic immediate-release/extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets (one tablet), 15/650mg (two tablets), or 30/1,300mg (four tablets) under fasted conditions
Trial: 26316698
Drug: Biphasic immediate-release/extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets under fed conditions
Trial: 24079037
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.9% sodium chloride solution in WLL)
Trial: 20076856
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg)
Trial: 16387583
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (100 mug twice daily)
Trial: 16387583
Drug: Montelukast (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5-10 mg nightly, age dependent)
Trial: 15057400
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam (Group B)
Trial: 15057400
Drug: No pre‐medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre‐medication (Group A)
Trial: 3882899
Drug: Pentobarbital treatment
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital treatment (27 cases)
Trial: 22053074
Drug: Transdermal GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal GTN (0.6 mg/h)
Trial: 22053074
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of antioxidant vitamin C with rosiglitazone and GTN
Trial: 20473738
Drug: Tanreqing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing Injection (TRQI)
Trial: 20473738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group A (15 mg ambroxol hydrochloride twice a day)
Trial: 20473738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group B (conventional Western medicine treatment only)
Trial: 18269068
Drug: Treatment strategies
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategies for patients with acute decompensated heart failure and poor renal function
Trial: 12501880
Drug: Once-weekly alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly alendronate 70 mg
Trial: 12412806
Drug: Twice-weekly alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly alendronate 35 mg
Trial: 12412806
Drug: Daily alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily alendronate 10 mg
Trial: 10902536
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal (250g curd, 150g yoghurt, 3 slices pineapple, 2 breakfast rolls, 2 cups of coffee, 10g coffee cream, 20g butter, 50g jam, 20g honey; 580mg Ca)
Trial: 10902536
Drug: Lactogluconate effervescent
RxNorm normalized name: calcium galactogluconate bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactogluconate effervescent tablet (500mg Ca)
Trial: 7595245
Drug: Orthographic similarity
RxNorm normalized name: Antigonadotropins and similar agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthographic similarity (e.g., keller‐KELLER, cellar‐ladle)
Trial: 7595245
Drug: Morphological relatedness
RxNorm normalized name: Emergency Preparedness KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphological relatedness (e.g., kellen‐KELLE, ladles‐ladle)
Trial: 3711379
Drug: Oral 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8‐methoxypsoralen
Trial: 31635021
Drug: BoNT/A treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A treatment for chronic migraine
Trial: 27390050
Drug: Oppanol® PIB‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oppanol® PIB‐containing transdermal therapeutic system (TTS) formulation (0.3 mg clonidine/24 h)
Trial: 27390050
Drug: All patch
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patch types (T1/R1, R1/T1, T2, R2)
Trial: 24509969
Drug: Topical scar
RxNorm normalized name: Mederma Advanced Scar Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical scar gel containing extract of Allium cepae, allantoin, and heparin (Contractubex) applied twice daily
Trial: 21689142
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg for 10 days
Trial: 21689142
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg for 10 days
Trial: 18467080
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy plus chemotherapy
Trial: 7844217
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (50 mg/day for 5 days) and IUI (clomiphene/IUI group)
Trial: 7844217
Drug: Late low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Late low-dose pure follicle stimulating hormone (FSH, 75 IU/day from day cycle 7 until the leading follicle reached > 17 mm in diameter) and IUI (FSH/IUI group)
Trial: 3395259
Drug: Controlled-release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbidopa/levodopa 50/200 (SINEMET CR)
Trial: 31506853
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) in addition to standard medical care
Trial: 26132687
Drug: D-Cycloserine plus
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine plus exposure therapy (n = 20)
Trial: 26132687
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus exposure therapy (n = 16)
Trial: 24133627
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100 mg/day for 6-10 months)
Trial: 21367625
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg three times a day (titrated to 100 mg after one month)
Trial: 18326618
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE), 890 mg polyphenols and 366 mg EGCG, taken as 3 capsules before exercise
Trial: 12716269
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment (individually tailored remedy)
Trial: 10715299
Drug: IV methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV methotrexate (MTX) 1,000 mg/m2 plus IV mercaptopurine (MP) 1,000 mg/m2 (regimen A)
Trial: 10715299
Drug: IV methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV methotrexate (MTX) 1,000 mg/m2 alone (regimen C)
Trial: 26716365
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages for adherence for 21 days plus usual care
Trial: 23299530
Drug: Cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 20 mg with mFOLFOX6
Trial: 23299530
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg with mFOLFOX6
Trial: 23299530
Drug: Cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 20 mg
Trial: 19900491
Drug: GLP-2 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (450 nmol subcutaneous)
Trial: 15935648
Drug: Chlorhexidine spray
RxNorm normalized name: chlorhexidine Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine spray (0.5% in alcoholic solution)
Trial: 15935648
Drug: Chlorhexidine sachet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine sachet (0.05% aqueous solution)
Trial: 12930191
Drug: 180 g
RxNorm normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 g EGb 761
Trial: 1860302
Drug: Ranitidine pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine pretreatment (five 150-mg oral doses given every 12 hours)
Trial: 7334938
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 2 mg of micronized oestradiol and 1 mg of micronized oestriol (Estrofem)
Trial: 7334938
Drug: Aqueous suspension
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suspension of the same micronized hormones
Trial: 26764121
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) 30 mg administered every 7 days (Q7D)
Trial: 26764121
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) 30 mg administered every 5 days (Q5D)
Trial: 23809278
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) 30 mg
Trial: 24796046
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + Zhangmo decoction group (C)
Trial: 24796046
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + Zhangmo decoction + warm needling group (D)
Trial: 24796046
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + progynova group (B)
Trial: 18815997
Drug: 14-week integrated
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-week integrated treatment targeting anger and addictions (i.e., both gambling and substance use)
Trial: 18815997
Drug: Specialized treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized treatment-as-usual (TAU) for gambling and substance use
Trial: 17189398
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sorafenib twice daily plus best supportive care
Trial: 17189398
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sorafenib twice daily
Trial: 10226868
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 or 8 mg once daily
Trial: 15700491
Drug: Doxazosin standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin standard 1 mg to 8 mg once daily
Trial: 8765624
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (6 mg/kg per week)
Trial: 8765624
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous lactate (elemental iron, 12 mg/kg per day)
Trial: 28642209
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral naltrexone (50mg)
Trial: 26138865
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 mg BID
Trial: 26138865
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg QD
Trial: 21482091
Drug: 18 μg
RxNorm normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 μg of tiotropium bromide plus 200 μg salbutamol
Trial: 12919709
Drug: Cyclic therapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic therapy with etidronate (400 mg/day for 2 weeks followed by 500 mg/day of calcium lactate for 12 weeks, repeated every 14 weeks)
Trial: 3824375
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice daily after breakfast and at bedtime
Trial: 9041463
Drug: Low-dose IFN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose IFN, 6 x 10(6) U/m2 daily x 3 every 4 weeks
Trial: 9041463
Drug: High-dose IFN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN, 12 x 10(6) U/m2, 3 x/week
Trial: 9041463
Drug: Both low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both low-dose and high-dose IFN
Trial: 9041463
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving >= 6 weeks of therapy
Trial: 1424422
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg/day)
Trial: 6366561
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 mg per day)
Trial: 6366561
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg per day)
Trial: 22573431
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (400 IU/day) and Calcium (1,000 mg elemental)
Trial: 20147467
Drug: Vegetable portion
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable portion size increased (180, 270, or 360 g)
Trial: 20147467
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in vegetable energy density (0.8 or 0.4 kcal/g)
Trial: 20147467
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of substitution and reduction in energy density
Trial: 7738889
Drug: Intravenous cholangiography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cholangiography (IVC)
Trial: 1917621
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment time within 49 days (≤ 7 weeks)
Trial: 1917621
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment time 50 to 63 days (8 to 9 weeks)
Trial: 1917621
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment time ≥ 64 days (> 9 weeks)
Trial: 25668435
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration (24 IU)
Trial: 19336851
Drug: 2% amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% amitriptyline gel
Trial: 15021286
Drug: 25G needle
RxNorm normalized name: NEEDLE 25G 1IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25G needle injection
Trial: 2510329
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg
Trial: 28984772
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: fluid‐air exchange tube connected to a 1 mL syringe with the plunger removed and the tip dilated with a hemostat.
Trial: 21168116
Drug: Qigong training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong training for half an hour daily for six weeks
Trial: 18997197
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg daily)
Trial: 9759611
Drug: GPIIb/IIIa‐inhibitor MK383
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPIIb/IIIa‐inhibitor MK383